Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.

The European Medicines Agency (EMA) has agreed to review GSK’s application of expanding Nucala’s (mepolizumab) use as add-on maintenance for individuals with chronic obstructive pulmonary disease ...

The price you pay for Nucala may depend on factors such as your health or medical insurance and the pharmacy used. Financial assistance may be available to help you with the cost of Nucala.

GSK said on Monday that the European Medicines Agency has accepted its application to expand the use of ‘Nucala’, or mepolizumab, to include patients with chronic obstructive pulmonary disease (COPD) ...

Please provide your email address to receive an email when new articles are posted on . Depemokimab’s mechanism of action is similar to mepolizumab. Three adverse events led to discontinuation ...

Please provide your email address to receive an email when new articles are posted on . Patients began with mepolizumab or benralizumab before switching to continuing with benralizumab at week 52.

(Alliance News) - GSK PLC on Monday said it has had an application to expand the use of mepolizumab for the treatment of chronic obstructive pulmonary disease accepted for review by the European ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

The FDA is reviewing the BLA for mepolizumab, an interleukin-5 (IL-5) antagonist monoclonal antibody, as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD) with an ...

EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...